| Budget Amount *help |
¥16,770,000 (Direct Cost: ¥12,900,000、Indirect Cost: ¥3,870,000)
Fiscal Year 2017: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2016: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2015: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
|
|---|
| Outline of Final Research Achievements |
The purposes of this study are to clarify a molecular mechanism determining anti-EGFR antibody treatment-resistant of high DNA methylation type colorectal cancer and to search for a method overcoming the resistance. As a result of comprehensive gene expression analysis, we determined that a specific subgroup correlated with effects of standard 1st-line treatment and of 3rd-line anti-EGFR antibody of the unresectable advanced or recurrent colorectal cancer and the second treatment. And as a result of comprehensive miRNA expression analysis, we identified that miR-193a-3p strongly correlated with BRAF mutation tumor, and that lower expression of miR-193a-3p associated with refractory of the anti-EGFR antibody. We are going to develop the study more in future.
|
